Drug intelligence / Profile preview

CD 650

Development stage: Preclinical
Lead developer: Chodang Pharm

Overview

CD 650 is an investigational drug candidate being developed by Chodang Pharmaceutical Industry for the treatment of colorectal cancer. As of early 2024, the program is in the preclinical research stage. Publicly available information regarding its pharmacological profile, including its specific modality (e.g., small molecule or biologic) and molecular target, has not been disclosed by the developer. The candidate is part of Chodang's oncology pipeline, which also includes research into treatments for blood cancer.

Beyond the preview

Go deeper on CD 650.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on CD 650.

Explore the full profile